HEPA — Hepion Pharmaceuticals, Inc.
$0.11
$-0.03 (-18.57%)
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV.
Market Cap
$14.05M
Forward P/E
-0.0x
52-Week Range
N/A
HEPA Price History
Revenue vs. Net Income
$0
Revenue · FY2023
Annual. Net margin is shown under each year.
Free Cash Flow
-$40.9M
FCF · FY2023
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-385.2%
ROCE · FY2023
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.7x
Assets ÷ liabilities · FY2023
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+4.2%
Dilution · FY2023
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
